{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:12Z","timestamp":1792783152103,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica Do Paran\u00e1","id":[{"id":"https:\/\/ror.org\/02x1vjk79","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rev Endocr Metab Disord"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Data from current literature have suggested a positive association between Steatotic Liver Disease (SLD) and Chronic Kidney Disease (CKD). In 2023, a consensus of experts suggested that the term metabolic associated steatotic liver disease (MASLD) be used instead of non-alcoholic fatty liver disease (NAFLD), a term that had long been used to indicate the situation of hepatic steatosis not related to alcohol consumption or secondary to another etiology. The majority of hepatologists accepted this suggestion. To critically analyze this described association and compare the impact of change in criteria, we performed a systematic review followed by meta-analysis of incidence studies that evaluated the occurrence of new cases of CKD in patients diagnosed with NAFLD and MAFLD\/MASLD. We searched the PubMed, LILACS, SciELO, and Cochrane Library databases for longitudinal studies published through June 2025 that included groups with NAFLD, MAFLD, and\/or MASLD, as well as a control group, in the adult population without CKD at baseline. Among 2,099 studies found, twenty met the inclusion criteria. Compared to the patient\u2019s control group, the risk ratio (RR) for incidence of CKD in the group with MAFLD, MASLD, and NAFLD was 1.29 (1.18\u20131.40), 1.16 (1.12\u20131.19) and 1.25 (1.14\u20131.36), respectively. In a new analysis grouping MASLD with MAFLD to assess the impact of the terminology shift, the results remained similar. This review demonstrates that SLD is associated with the risk of developing CKD, regardless of classification. However, this connection needs further elucidation of its mechanisms to comprehend it better and prevent its impact.<\/jats:p>","DOI":"10.1007\/s11154-026-10059-0","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:52:54Z","timestamp":1781142774000},"page":"999-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between metabolic dysfunction-associated steatotic liver disease\/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"27","author":[{"suffix":"Jr.","given":"Andr\u00e9 O.","family":"Soares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davi A. C.","family":"Loli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo R.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Daher Alvares","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Roberto","family":"Bignardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"10059_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"10059_CR2","doi-asserted-by":"publisher","unstructured":"Bilson J, Hydes TJ, McDonnell D, et al. Impact of Metabolic Syndrome Traits on Kidney Disease Risk in Individuals with MASLD: A UK Biobank Study. Liver Int. 2025;45. https:\/\/doi.org\/10.1111\/liv.16159.","DOI":"10.1111\/liv.16159"},{"key":"10059_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra2412865","volume":"393","author":"G Targher","year":"2025","unstructured":"Targher G, Valenti L, Byrne CD. Metabolic Dysfunction\u2013Associated Steatotic Liver Disease. N Engl J Med. 2025;393:683\u201398. https:\/\/doi.org\/10.1056\/NEJMra2412865.","journal-title":"N Engl J Med"},{"key":"10059_CR4","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J Hepatol. 2024;80:e76\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.026.","journal-title":"J Hepatol"},{"key":"10059_CR5","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","volume":"80","author":"R Hashida","year":"2024","unstructured":"Hashida R, Nakano D, Kawaguchi M, et al. Changing from NAFLD to MASLD: The implications for health-related quality of life data. J Hepatol. 2024;80:e249\u201351.","journal-title":"J Hepatol"},{"key":"10059_CR6","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","journal-title":"J Hepatol"},{"key":"10059_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.12.018","author":"T Kimura","year":"2025","unstructured":"Kimura T, Tamaki N, Wakabayashi S-I, et al. Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD). Clin Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.018.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10059_CR8","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.obpill.2025.100164","volume":"14","author":"J Panganiban","year":"2025","unstructured":"Panganiban J, Kehar M, Ibrahim SH, Hartmann P, Sood S, Hassan S, Ramirez CM, Kohli R, Censani M, Mauney E, Cuda S, Karjoo S. Metabolic dysfunction-associated steatotic liver disease (MASLD) in children with obesity: An Obesity Medicine Association (OMA) and expert joint perspective 2025. Obes Pillars. 2025;14:100164.","journal-title":"Obes Pillars"},{"issue":"1","key":"10059_CR9","doi-asserted-by":"publisher","first-page":"e0181","DOI":"10.1097\/CLD.0000000000000181","volume":"23","author":"KM LaeeqT, Tun","year":"2024","unstructured":"Laeeq T,Tun KM. Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. Clin Liver Dis (Hoboken). 2024;23(1):e0181. https:\/\/doi.org\/10.1097\/CLD.0000000000000181","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10059_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrneph.2016.145","volume":"12","author":"F Artunc","year":"2016","unstructured":"Artunc F, Schleicher E, Weigert C, et al. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol. 2016;12:721\u201337.","journal-title":"Nat Rev Nephrol"},{"key":"10059_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3350\/cmh.2024.0782","volume":"31","author":"WY Chen","year":"2025","unstructured":"Chen WY, Zhang JH, Chen LL, et al. Bioactive metabolites: A clue to the link between MASLD and CKD? Clin. Mol Hepatol. 2025;31:56\u201373.","journal-title":"Mol Hepatol"},{"key":"10059_CR12","doi-asserted-by":"crossref","unstructured":"Mantovani A, Targher G. PNPLA3 variation and kidney disease. Liver International 45; 2025.","DOI":"10.1111\/liv.16010"},{"key":"10059_CR13","doi-asserted-by":"crossref","unstructured":"Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease. Improving Global Outcomes (KDIGO); 2005.","DOI":"10.1111\/j.1523-1755.2005.00365.x"},{"key":"10059_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","DOI":"10.1016\/j.ijsu.2021.105906"},{"key":"10059_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"G Marchesini","year":"2016","unstructured":"Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388\u2013402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","journal-title":"J Hepatol"},{"key":"10059_CR16","doi-asserted-by":"publisher","first-page":"101547","DOI":"10.1016\/j.eclinm.2022.101547","volume":"51","author":"Y-T Cao","year":"2022","unstructured":"Cao Y-T, Xiang L-L, Qi F, et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. EClinicalMedicine. 2022;51:101547.","journal-title":"EClinicalMedicine"},{"key":"10059_CR17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"F Tacke","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V, et al. EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492\u2013542. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J Hepatol"},{"key":"10059_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/S10654-010-9491-Z\/METRICS","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135. https:\/\/doi.org\/10.1007\/S10654-010-9491-Z\/METRICS.","journal-title":"Eur J Epidemiol"},{"key":"10059_CR19","unstructured":"Chapter 6. Choosing effect measures and computing estimates of effect | Cochrane. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-06. Accessed 9 Oct 2025."},{"key":"10059_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.6133\/APJCN.202504_34(2).0013","volume":"34","author":"H Cherif","year":"2025","unstructured":"Cherif H, Dziri C. Improving meta-analysis methodology: The necessity of prediction intervals and homogeneous data selection. Asia Pac J Clin Nutr. 2025;34:262. https:\/\/doi.org\/10.6133\/APJCN.202504_34(2).0013.","journal-title":"Asia Pac J Clin Nutr"},{"key":"10059_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1177\/17407745080914","volume":"5","author":"BK Moser","year":"2008","unstructured":"Moser BK, McCann MH. Reformulating the hazard ratio to enhance communication with clinical investigators. Clin Trails. 2008;5:248\u201352. https:\/\/doi.org\/10.1177\/17407745080914.","journal-title":"Clin Trails"},{"key":"10059_CR22","doi-asserted-by":"publisher","first-page":"0","DOI":"10.21037\/hbsn-23-558","volume":"0","author":"JH Heo","year":"2024","unstructured":"Heo JH, Lee MY, Kim SH, et al. Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study. Hepatobiliary Surg Nutr. 2024;0:0\u20130. https:\/\/doi.org\/10.21037\/hbsn-23-558.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10059_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.clinre.2019.02.004","volume":"43","author":"K \u00d6nnerhag","year":"2019","unstructured":"\u00d6nnerhag K, Dreja K, Nilsson PM, Lindgren S. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. Clin Res Hepatol Gastroenterol. 2019;43:542\u201350. https:\/\/doi.org\/10.1016\/j.clinre.2019.02.004.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10059_CR24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1111\/liv.14125","volume":"39","author":"RM Wilechansky","year":"2019","unstructured":"Wilechansky RM, Pedley A, Massaro JM, et al. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver Int. 2019;39:1535\u201344. https:\/\/doi.org\/10.1111\/liv.14125.","journal-title":"Liver Int"},{"key":"10059_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.metabol.2007.11.022","volume":"57","author":"Y Chang","year":"2008","unstructured":"Chang Y, Ryu S, Sung E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57:569\u201376. https:\/\/doi.org\/10.1016\/j.metabol.2007.11.022.","journal-title":"Metabolism"},{"key":"10059_CR26","doi-asserted-by":"publisher","unstructured":"Kwon SY, Park J, Park SH, et al. MAFLD and NAFLD in the prediction of incident chronic kidney disease. Sci Rep. 2023;13. https:\/\/doi.org\/10.1038\/s41598-023-27762-6.","DOI":"10.1038\/s41598-023-27762-6"},{"key":"10059_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, et al. Association of MAFLD with Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China. J Clin Endocrinol Metab. 2022;107:88\u201397. https:\/\/doi.org\/10.1210\/clinem\/dgab641.","journal-title":"J Clin Endocrinol Metab"},{"key":"10059_CR28","doi-asserted-by":"publisher","unstructured":"Mikolasevic I, Domislovic V, Ruzic A, et al. Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. J Diabetes Complications. 2022;36. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108226.","DOI":"10.1016\/j.jdiacomp.2022.108226"},{"key":"10059_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4093\/dmj.2021.0130","volume":"46","author":"DH Seo","year":"2022","unstructured":"Seo DH, Suh YJ, Cho Y, et al. Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Diabetes Metab J. 2022;46:630\u20139. https:\/\/doi.org\/10.4093\/dmj.2021.0130.","journal-title":"Diabetes Metab J"},{"key":"10059_CR30","doi-asserted-by":"crossref","unstructured":"Sinn DH, Kang D, Jang HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease. A cohort study; 2017.","DOI":"10.1016\/j.jhep.2017.08.024"},{"key":"10059_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/ndt\/gfac188","volume":"38","author":"M Tanaka","year":"2022","unstructured":"Tanaka M, Mori K, Takahashi S, et al. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. Nephrol Dial Transpl. 2022;38:700\u201311. https:\/\/doi.org\/10.1093\/ndt\/gfac188.","journal-title":"Nephrol Dial Transpl"},{"key":"10059_CR32","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.2337\/dc13-2704","volume":"37","author":"G Targher","year":"2014","unstructured":"Targher G, Mantovani A, Pichiri I, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37:1729\u201336. https:\/\/doi.org\/10.2337\/dc13-2704.","journal-title":"Diabetes Care"},{"key":"10059_CR33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1681\/ASN.2007101155","volume":"19","author":"G Targher","year":"2008","unstructured":"Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564\u201370. https:\/\/doi.org\/10.1681\/ASN.2007101155.","journal-title":"J Am Soc Nephrol"},{"key":"10059_CR34","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang T, Liu Y, et al. Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction\u2013associated fatty liver disease: Results from two prospective cohorts. Diabetes Metabolic Syndrome: Clin Res Reviews. 2023;17. https:\/\/doi.org\/10.1016\/j.dsx.2023.102873.","DOI":"10.1016\/j.dsx.2023.102873"},{"key":"10059_CR35","doi-asserted-by":"publisher","first-page":"E3957","DOI":"10.1210\/clinem\/dgab425","volume":"106","author":"G Zuo","year":"2021","unstructured":"Zuo G, Xuan L, Xin Z, et al. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate with the Risk of Incident Chronic Kidney Disease. J Clin Endocrinol Metab. 2021;106:E3957\u201368. https:\/\/doi.org\/10.1210\/clinem\/dgab425.","journal-title":"J Clin Endocrinol Metab"},{"key":"10059_CR36","doi-asserted-by":"publisher","unstructured":"Saito H, Tanabe H, Kudo A, et al. High FIB4 index is an independent risk factor of diabetic kidney disease in type 2 diabetes. Sci Rep. 2021;11. https:\/\/doi.org\/10.1038\/s41598-021-88285-6.","DOI":"10.1038\/s41598-021-88285-6"},{"key":"10059_CR37","doi-asserted-by":"publisher","unstructured":"Gao J, Li Y, Zhang Y, et al. Severity and Remission of Metabolic Dysfunction\u2013Associated Fatty\/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. J Am Heart Assoc. 2024;13. https:\/\/doi.org\/10.1161\/JAHA.123.032604.","DOI":"10.1161\/JAHA.123.032604"},{"key":"10059_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jdi.13678","volume":"13","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Hamaguchi M, Okamura T, et al. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig. 2022;13:308\u201316. https:\/\/doi.org\/10.1111\/jdi.13678.","journal-title":"J Diabetes Investig"},{"key":"10059_CR39","doi-asserted-by":"publisher","unstructured":"Wei S, Song J, Xie Y, et al. The Role of Metabolic Dysfunction\u2013Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study. JMIR Public Health Surveill. 2023;9. https:\/\/doi.org\/10.2196\/45050.","DOI":"10.2196\/45050"},{"key":"10059_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110563","author":"S Wei","year":"2023","unstructured":"Wei S, Song J, Xie Y, et al. Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes. Diabetes Res Clin Pract. 2023. https:\/\/doi.org\/10.1016\/j.diabres.2023.110563. 197:.","journal-title":"Diabetes Res Clin Pract"},{"key":"10059_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/hepr.14097","volume":"55","author":"K Mori","year":"2024","unstructured":"Mori K, Tanaka M, Sato T, et al. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. Hepatol Res. 2024;55:34\u201345. https:\/\/doi.org\/10.1111\/hepr.14097.","journal-title":"Hepatol Res"},{"key":"10059_CR42","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.jhep.2024.02.010","volume":"80","author":"R Hashida","year":"2024","unstructured":"Hashida R, Nakano D, Kawaguchi M, et al. Changing from NAFLD to MASLD: The implications for health-related quality of life data. J Hepatol. 2024;80:e249\u201351. https:\/\/doi.org\/10.1016\/j.jhep.2024.02.010.","journal-title":"J Hepatol"},{"key":"10059_CR43","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2023","unstructured":"Song SJ, Lai JCT, Wong GLH, et al. Can we use old NAFLD data under the new MASLD. definition? J Hepatol. 2023;80:e54\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021.","journal-title":"definition? J Hepatol"},{"key":"10059_CR44","doi-asserted-by":"publisher","first-page":"e13649","DOI":"10.1111\/OBR.13649","volume":"25","author":"FG Scurt","year":"2023","unstructured":"Scurt FG, Ganz MJ, Herzog C, et al. Association of metabolic syndrome and chronic kidney disease. Obes Rev. 2023;25:e13649. https:\/\/doi.org\/10.1111\/OBR.13649. ;WEBSITE:WEBSITE:PERICLES;JOURNAL:JOURNAL:1467789X;WGROUP:STRING:PUBLICATION.","journal-title":"Obes Rev"},{"key":"10059_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.trsl.2016.12.004","volume":"183","author":"X Zhang","year":"2017","unstructured":"Zhang X, Lerman LO. The metabolic syndrome and chronic kidney disease. Translational Res. 2017;183:14\u201325.","journal-title":"Translational Res"},{"key":"10059_CR46","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40200-023-01348-5","volume":"23","author":"A Valizadeh","year":"2024","unstructured":"Valizadeh A, Nikoohemmat M, Ebadinejad A, et al. Metabolic syndrome as a risk factor for the development of kidney dysfunction: a meta-analysis of observational cohort studies. J Diabetes Metab Disord. 2024;23:215\u201327.","journal-title":"J Diabetes Metab Disord"},{"key":"10059_CR47","doi-asserted-by":"publisher","first-page":"119053","DOI":"10.1016\/j.atherosclerosis.2024.119053","volume":"400","author":"C Iturbe-ReyS, Maccali","year":"2025","unstructured":"Iturbe-Rey S, Maccali C, Arrese M, Aspichueta P, Oliveira CP, Castro RE, Lapitz A, Izquierdo-Sanchez L, Bujanda L, Perugorria MJ, Banales JM, Rodrigues PM. Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD). Atherosclerosis. 2025;400:119053. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.119053","journal-title":"Atherosclerosis"},{"key":"10059_CR48","doi-asserted-by":"publisher","unstructured":"Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, Pennisi G, Grimaudo S, Petta S. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023 Jan 28;14:20420188221145549. https:\/\/doi.org\/10.1177\/20420188221145549","DOI":"10.1177\/20420188221145549"},{"issue":"7","key":"10059_CR49","doi-asserted-by":"publisher","first-page":"e0484","DOI":"10.1097\/HC9.0000000000000484","volume":"8","author":"Z ZhangR, Yan","year":"2024","unstructured":"Zhang R, Yan Z, Zhong H, Luo R, Liu W, Xiong S, Liu Q, Liu M. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment. Hepatol Commun. 2024;8(7):e0484. https:\/\/doi.org\/10.1097\/HC9.0000000000000484","journal-title":"Hepatol Commun"},{"key":"10059_CR50","doi-asserted-by":"publisher","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024;12:1433857. https:\/\/doi.org\/10.3389\/fcell.2024.1433857","journal-title":"Front Cell Dev Biol"},{"key":"10059_CR51","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75:3313\u201327.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10059_CR52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3390\/medicina58050641","volume":"58","author":"SI PetrescuM, Vlaicu","year":"2022","unstructured":"Petrescu M, Vlaicu SI, Cium\u0103rnean L, Milaciu MV, M\u0103rginean C, Florea M, Vesa \u0218C, Popa M. Chronic Inflammation-A Link between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Med (Kaunas). 2022;58(5):641. https:\/\/doi.org\/10.3390\/medicina58050641","journal-title":"Med (Kaunas)"},{"key":"10059_CR53","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/hep.23280","volume":"51","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications. Hepatology. 2010;51:679\u201389.","journal-title":"Hepatology"},{"key":"10059_CR54","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41575-019-0144-8","volume":"16","author":"AJ Sanyal","year":"2019","unstructured":"Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377\u201386.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10059_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms17040562","volume":"17","author":"M Marcuccilli","year":"2016","unstructured":"Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17:1\u201315. https:\/\/doi.org\/10.3390\/ijms17040562.","journal-title":"Int J Mol Sci"},{"key":"10059_CR56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","volume":"72","author":"CD Byrne","year":"2020","unstructured":"Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J Hepatol. 2020;72:785\u2013801.","journal-title":"J Hepatol"},{"key":"10059_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001680","author":"G Musso","year":"2014","unstructured":"Musso G, Gambino R, Tabibian JH, et al. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis. PLoS Med. 2014. https:\/\/doi.org\/10.1371\/journal.pmed.1001680. 11:.","journal-title":"PLoS Med"},{"key":"10059_CR58","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","volume":"21","author":"G Musso","year":"2015","unstructured":"Musso G, Cassader M, Cohney S, et al. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645\u201362.","journal-title":"Trends Mol Med"},{"issue":"18","key":"10059_CR59","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.3390\/ijerph16183415","volume":"16","author":"V Rosato","year":"2019","unstructured":"Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health. 2019;16(18):3415. https:\/\/doi.org\/10.3390\/ijerph16183415","journal-title":"Int J Environ Res Public Health"},{"key":"10059_CR60","doi-asserted-by":"publisher","unstructured":"Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic fatty liver disease and the kidney: A review. Biomedicines. 2021;9. https:\/\/doi.org\/10.3390\/biomedicines9101370.","DOI":"10.3390\/biomedicines9101370"},{"key":"10059_CR61","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/CEG.S226130","volume":"14","author":"A Cheung","year":"2021","unstructured":"Cheung A, Ahmed A. Nonalcoholic fatty liver disease and chronic kidney disease: A review of links and risks. Clin Exp Gastroenterol. 2021;14:457\u201365.","journal-title":"Clin Exp Gastroenterol"},{"key":"10059_CR62","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62:S47\u201364.","journal-title":"J Hepatol"},{"key":"10059_CR63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","volume":"71","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: An updated meta-analysis. Gut. 2020;71:156\u201362. https:\/\/doi.org\/10.1136\/gutjnl-2020-323082.","journal-title":"Gut"},{"key":"10059_CR64","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","volume":"79","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Zaza G, Byrne CD, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2017;79:64\u201376.","journal-title":"Metabolism"},{"key":"10059_CR65","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/hep.24452","volume":"54","author":"R Hernaez","year":"2011","unstructured":"Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;54:1082\u201390.","journal-title":"Hepatology"},{"key":"10059_CR66","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/nejmoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction\u2013Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/nejmoa2401943.","journal-title":"N Engl J Med"},{"key":"10059_CR67","unstructured":"FDA Approves Treatment for Serious Liver Disease Known as. \u2018MASH\u2019 | FDA. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. Accessed 2 Sep 2025."},{"key":"10059_CR68","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1097\/ms9.0000000000002770","volume":"87","author":"A Waheed","year":"2025","unstructured":"Waheed A, Gul MH, Shabbir MUB, et al. FDA approves Resmetirom: groundbreaking treatment for NASH liver scarring in moderate to advanced fibrosis. Annals Med Surg. 2025;87:1088\u201391. https:\/\/doi.org\/10.1097\/ms9.0000000000002770.","journal-title":"Annals Med Surg"},{"key":"10059_CR69","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Stepanova M, Taub RA, et al. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol. 2022;20:1354\u2013e13617. https:\/\/doi.org\/10.1016\/j.cgh.2021.07.039.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Reviews in Endocrine and Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10059-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11154-026-10059-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11154-026-10059-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:02:42Z","timestamp":1790442162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11154-026-10059-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10059"],"URL":"https:\/\/doi.org\/10.1007\/s11154-026-10059-0","relation":{},"ISSN":["1389-9155","1573-2606"],"issn-type":[{"value":"1389-9155","type":"print"},{"value":"1573-2606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"30 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}]}}